Clearside Biomedical, Inc. (CLSD)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| License and other revenue (includes 442 and 81 from a related party for the three months ended june 30, 2025 and 2024, respectively, and 448 and 156 for the six months ended june 30, 2025 and 2024, respectively.) | 492 | 2,330 | 1,038 | |
| Research and development (includes 243 and 503 to a related party for the three and six months ended june 30, 2024, respectively) | 1,584 | 4,463 | 4,128 | |
| General and administrative | 2,476 | 2,824 | 2,844 | |
| Cost of goods sold | - | 248 | - | |
| Total operating expenses | 4,060 | 7,535 | 6,972 | |
| Loss from operations | -3,568 | -5,205 | -5,934 | |
| Interest income | 115 | 163 | 338 | |
| Other income, net | 1,720 | 207 | - | |
| Non-cash interest expense on liability related to the sales of future royalties | 2,762 | 2,673 | 2,457 | |
| Loss before income taxes | -4,495 | -7,508 | - | |
| Income tax expense | - | 715 | - | |
| Other nonoperating income | - | - | 365 | |
| Net loss | -4,495 | -8,223 | 7,682 | |
| Unrealized gain on available-for-sale investments | - | - | 6 | |
| Other comprehensive income (loss), tax | - | - | 7,682 | |
| Net loss per share of common stock - basic | -0.06 | -0.11 | -0.1 | |
| Net loss per share of common stock - diluted | -0.06 | -0.11 | -0.1 | |
| Weighted average shares outstanding - basic | 77,844,055 | 76,921,843 | 74,745,415 | |
| Weighted average shares outstanding - diluted | 77,844,055 | 76,921,843 | 74,745,415 | |